Not all tests marketed as groundbreaking are ready for prime time.
The PSE EpiSwitch test—hailed as a potential game-changer—combines PSA testing with circulating chromosome analysis. Early data suggests that when it’s negative, the likelihood of prostate cancer may be lower.
But let’s not rush to conclusions. The study is small, the test is brand new, and the market pressure to monetize it is strong.
Intellectual Medicine
Not all tests marketed as groundbreaking are ready for prime time.
The PSE EpiSwitch test—hailed as a potential game-changer—combines PSA testing with circulating chromosome analysis. Early data suggests that when it’s negative, the likelihood of prostate cancer may be lower.
But let’s not rush to conclusions. The study is small, the test is brand new, and the market pressure to monetize it is strong.
Know more in this week’s episode of Intellectual Medicine. https://youtu.be/3swsTq4xr-k
#podcast #ProstateFacts #MensVitality #CancerChoices
7 months ago | [YT] | 0